For example, by comparing 37 BRCA1 mutant ovarian cancer patients with wild-type patients, it has been recently shown that survival of BRCA1 mutation carriers had no significant difference from wild-type cases [12], [13]. This evidence concerns the gene BRCA1 and ovarian carcinoma.